MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1, but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to superenhancers associated with genes such as IGH, IGK, IGL, TXNDC5/BMP6, FAM46C and FOXO3.
Introduction
The genome of multiple myeloma (MM) is characterized by primary translocations in ~40% of newly diagnosed patients that are considered initiating events and involve rearrangements of the immunoglobulin heavy chain (IGH) locus on 14q32. 1 The partners of these rearrangements include 11q (CCND1, 15%), 4p (FGFR3 and MMSET, 10%), 16q (MAF, 2-3%), 20q (MAFB, 1%) and 6q (CCND3, 1%). These rearrangements result in placement of the IGH super-enhancers next to a partner oncogene, resulting in its over-expression. 2 The rearrangements predominantly occur in the switch regions 5' of the constant regions in the IGH locus, where a high concentration of activation-induced cytidine deaminase (AID) binding motifs are found. Normally, AID binds to the switch regions leading to class switch recombination, resulting in antibody isotype switching. 3 However, abnormal breaks in the switch regions, resulting from AID activity, results in IGH translocations. 4 Secondary translocations involving MYC, located on 8q24.21, also occur in MM and are associated with disease progression and increased expression of MYC. [5] [6] [7] [8] MYC encodes a transcriptional regulator and has been shown to be involved in proliferation, differentiation, protein synthesis, apoptosis, adhesion, DNA repair, chromosomal instability, angiogenesis and metastasis. [9] [10] [11] [12] [13] Translocations and high expression of MYC are associated with poor outcome, especially in MM where it is a marker of aggressive disease. 5, 14 MYC can be deregulated by a range of different mechanisms including chromosomal rearrangement 5, 6 , copy-number gain/amplification 15, 16 , protein stabilization 17 , via secondary messengers involved in MYC transcription 18 or miRNAs such as PVT1. 19, 20 The frequency of MYC rearrangements seen in newly diagnosed MM (NDMM) varies from 15-50% and is dependent on the method used to identify it. 5, 6, 21, 22 The data is consistent with MYC rearrangements being rare in the asymptomatic stages such as MGUS and smoldering myeloma 21 , and increases as the disease progresses with a high incidence (>80%) in myeloma cell lines. [22] [23] [24] MYC rearrangements are not only seen in MM but are also frequent in lymphomas where they have been studied extensively. 25, 26 In Burkitt's lymphoma and diffuse large B cell lymphoma t (8;14) rearrangements between IGH and MYC have also been shown to result from abnormal class switch recombination. 27 The relevance of AID in these rearrangements is supported by data from IL-6 transgenic mice which also develop MYC/IGH rearrangements in B cells.
Rearrangements, however, do not occur if the mice are also deficient in AID, indicating that class switch recombination via AID is key in generating these rearrangements. 4, 28 In MM, while karyotypic abnormalities similar to that observed in Burkitt's lymphoma are seen, variant structures can also be detected, suggesting that the mechanism of rearrangement in MM may not be identical to lymphoma. 29 Indeed, MYC rearrangements are not predominantly considered primary translocations in MM, often developing at later stages in the disease 22 , whereas in lymphoma they are considered primary events. 27 We and others have previously shown that MYC translocations result in the juxtaposition of immunoglobulin loci super-enhancers to MYC resulting in its over-expression. 6, 30 However, the details of breakpoint locations, the presence of copy-number abnormalities and the chromatin landscape of the rearrangement have not been well-characterized. In the present study, we have analyzed a large dataset of 1267 NDMM patients to determine the genomic architecture of MYC rearrangements and their effect on the expression of this proto-oncogene.
Methods

Patient Samples and Next Generation Sequencing
Total of 1267 NDMM patients were included in this study after informed consent and the study was approved by the Institutional Review Board at the University of Arkansas for Medical Sciences. Plasma cell were isolated from bone marrow by magnetic-activated cell sorting using CD138 + marker, AutoMACS Pro (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) or Robosep (STEMCELL Technologies, Vancouver, Canada). DNA from peripheral blood was used as a control sample for each patient to exclude germline variants. Three paired-end read sequencing platforms were combined without overlapping patients, namely targeted sequencing, whole exome sequencing, and low depth, long insert whole genome sequencing (Supplementary Methods). Additional expression data were available through either gene expression microarrays (Affymetrix, Santa Clara, CA, USA) or RNA-sequencing. An overall summary of methods, number of patients and external datasets are shown in Supplementary Figure 1 . Patients' characteristics are summarized in Supplementary Table 1 and MYC region capture is illustrated in
Patient Derived Xenografts
Patient derived xenografts were generated by passaging primary patient CD138+ selected cells through the previously described SCID-rab myeloma mouse model. 31 Tumors were dissected from the mouse, and pieces dispersed into a single cell population using a Kontes disposable tissue grinder. Cells were filtered through a 70 μm sterile filter, washed twice in PBS, treated with red cell lysis buffer, washed twice more, and treated immediately with Annexin V coated magnetic beads (Miltenyi Biotec), resulting in a population of cells with a viability >95%, as checked by flow cytometry. Passaged cells underwent CD138+ selection before being processed for 10x
Genomics whole genome sequencing, RNA-sequencing, and ChIP-seq.
ChIP-seq
ChIP-seq was performed on the myeloma cell lines KMS11 and MM.1S as well as a PDX sample with a MYC rearrangement identified by whole genome sequencing. 1x10 7 cells per mark were fixed in a 1% formaldehyde solution, followed by the addition of glycine to a final concentration of 0.125 M. Cells were washed and resuspended in PBS containing 0.5% lgepal with 1% PMSF, before being pelleted and frozen at -80 o C. ChIP-seq for the histone marks H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K27Ac, and H3K36me3 (Active Motif, Carlsbad, CA, USA), as well as the super-enhancer proteins BRD4 and MED1 (Bethyl, Montgomer, TX, USA), and the transcription factor MYC (Santa Cruz Biotechnology, Dallas, TX, USA) were performed by Active Motif. Controls without antibody input were performed to ensure data quality.
Data Analysis
Data analysis was performed as described previously, with minor differences between sequencing modalities. 32 For details see Supplementary Methods.
Statistical Analysis
Basic statistical analysis was performed using GraphPad Prism 7.01 (GraphPad Software, San Diego, CA, USA), R 3.4.4 and/or RStudio 1.1.442. Fisher's exact test, the Mann-Whitney U test, Spearman's rank correlation and Log-Rank test with Benjamini-Hochberg adjustment were used for data analysis and P values ≤0.05 were considered statistically significant.
Data Access
Sequencing data have been deposited in the European Genomic Archive under the accession numbers EGAS00001001147, EGAS00001002859, or at dbGAP under Accession phs000748.v5.p4.
Results
MYC Rearrangements Are Usually Present as Inter-Chromosomal Translocations, Co-
Occur with Secondary Genetic Events and Are Associated with Shorter Survival in Non-
Hyperdiploid Cases.
We examined a set of 1267 NDMM patient samples that had undergone either whole genome sequencing, exome sequencing, or targeted sequencing, of which the latter two methods involved The frequency of 8q24 abnormalities was significantly increased across ISS stages (I -28.6%, II -37.5% and III -41.6%, P<0.001), and were higher in the IMWG high-risk (34.6%) and standardrisk (28.1%) groups than in the low-risk group (23.6%, P<0.05). The association of 8q24 abnormalities with these negative prognostic factors may suggest a worse outcome of patients with 8q24 abnormalities, however analysis of this did not confirm the assumption in this dataset (Supplementary Figure 4A) . Also, 8q24 abnormalities were associated with lower, rather than higher, NF-kB pathway activation (Supplementary Figure 3) . Additional analysis, however, showed a significant effect of 8q24 abnormalities within the non-hyperdiploid sub-group ( Figure   1A ).
Translocations were found in 25.2% (319/1267) of samples and occurred most frequently as interchromosomal translocations involving 2 to 5 chromosomes (90.3%, 288/319), but 4.4% (14/319) were highly complex and involved more than 5 chromosomal loci, 
IGH-MYC Translocation Breakpoints Have a Distinct Distribution Compared to Primary
Translocations and Involve Recurrent Partners with Known Super-Enhancers.
A total of 149 chromosomal loci were found to be involved in MYC translocations (Figure 2A ; Supplementary Table 5 . Each of these non-Ig loci were confirmed to contain highly-expressed genes in MM using RNA-sequencing data, being present in >95% of patients with log2 normalized counts >10. All of the loci except for IGK had super-enhancers previously identified in the MM.1S cell line. 67.2% (205/305) of cases with non-complex translocation (5 or less loci involved) had at least one of these super-enhancers involved in the translocation. Another five partners were present in 5-10 cases, three of which overlapped with the highly-expressed genes FCHSD2, FBXW7 and SERTAD2, which are associated with known super-enhancers. 30 Interestingly, 13 samples had complex MYC translocations with more than one of these superenhancers. Also, eight samples had rearrangements involving IGH, MYC and CCND1, and four samples had rearrangements with IGH, MYC and MAF, indicating that they may occur as primary events early in the disease process. All oncogenes involved in these translocations show high expression (Supplementary This indicates that the MYC translocations are likely independent of AID and occur in a manner that is distinct to that of the primary translocations, Figure 4A -B.
MYC Breakpoints Show Evidence of Recombination through Microhomology.
It is known that class switch recombination breakpoints in B cells occur through AID and nonhomologous end joining (NHEJ), resulting in blunt ended DNA being ligated together. 33 As the MYC breakpoints identified here do not align to switch regions, and are presumably not mediated by AID, we examined the aligned breakpoints to determine if they were constructed through blunt ended joining or other mechanisms. In comparison to re-aligned t(4;14), t(6;14), t(11;14), t (14;16) and t (14;20) breakpoints, which are mediated by AID and NHEJ, the MYC breakpoints had significantly fewer blunt ended rearrangements (54.1% vs. 27.7%, P<0.001) and significantly more rearrangements with at least two nucleotides of homology (25.4% vs. 45.8%) between the chromosomes, Figure 4C . Homologous sequences between chromosomes of up to 12 nts were found. Representative alignments of rearrangements are shown in the Supplementary Alignments. These homologous sequences are representative of microhomology-mediated end joining (MMEJ), which is a mechanism more common to all secondary translocation events, There was no evidence of an AID motif cluster at the second hotspot, which could have explained the enrichment for Ig partners and there was no effect of the breakpoint position on patient outcome (Supplementary Figure 4E) .
Tandem-duplication breakpoints were enriched at the second hotspot (69.0% of breakpoints), Figure 5 and Supplementary Figures 7-8 , as have been noted in MM cell lines previously. 34 Conversely, deletion breakpoints were enriched at the first hotspot (30.5%) and at an additional hotspot centromeric of MYC (chr8:126.3-126.4 Mb). Inversion breakpoints were equally spread across all three hotspots.
By examining histone marks from the U266 cell line and four myeloma samples, for which we generated ChIP-seq histone mark data, there was also a link with accessible chromatin marks (H3K4me1, H3K4me3, H3K27ac and H3K36me3), DNaseI hypersensitivity sites and all three breakpoint hotspots, indicating that rearrangements may be more likely to happen in highly accessible, transcribed regions, Figure 5 .
Disruption of Topologically Associated Domains by MYC Rearrangements.
Topologically associated domains (TADs) have been shown to contain DNA elements that are more likely to interact with one another. Disruption of these TADs may bring super-enhancer elements into the same TAD as MYC, resulting in its increased expression. We examined the super-enhancers from the MM.1S cell line and TADs from RPMI-8226 and U266 cell lines and integrated MYC breakpoints.
On the six frequent MYC translocation partner loci, breakpoints were clustered near to the superenhancer and within the same TAD as the super-enhancer, Figure 6 . At 8q24, the translocation breakpoints, at the two hotspots, were clustered within the TAD containing MYC and PVT1. The resulting rearrangements would bring the super-enhancer from the partner loci adjacent to MYC, resulting in the formation of a Neo-TAD ( Figure 7B) and over-expression of MYC.
We identified a patient derived xenograft sample with a t(4;8) that resulted in insertion of 3 regions of chromosome 4 next to MYC, Figure 7A . This resulted in the super-enhancer from PCDH10, defined by the presence of H3K27Ac and MED1 marks, being placed next to MYC, resulting in over-expression. This shows for the first time in a patient sample a rearrangement that confirms the importance of placing of a super-enhancer next to MYC.
Lastly, deletions at 8q24 centromeric of MYC are present in 2.9% (36/1249) of samples, Figure   5 and Supplementary Figure 7 The biological consequence of rearrangements at 8q24 is thought to be increased expression of MYC, so we examined the available CoMMpass study RNA-sequencing data, Figure 3 , and a set of microarray data, Supplementary Figure 6 , and categorized samples by type and location of breakpoints. In addition to MYC, we examined the expression of other genes in the regions, but only found significant increases in MYC and the non-coding RNA, PVT1, Figure 3A -F, which were associated with particular types of rearrangements. Expression level of these two genes showed a significant but weak correlation (r=0.4, P<0.001).
The six MYC partner loci present in >10 samples (IGH, IGK, IGL, TXNDC5/BMP6, FOXO3 and FAM46C) had significantly higher expression of MYC (P<0.001) and PVT1 (P<0.001) compared to those without rearrangements or less frequent partners, Figure 3B ,E. Complex rearrangements involving more than five loci also resulted in higher expression of MYC (P<0.001) and PVT1 (P=0.02) compared to those without rearrangements, at levels equivalent to the frequent translocation partners indicating a selection pressure on these six loci for increased MYC expression. There was no difference in expression between samples with breakpoints at the hotspot around MYC or telomeric of MYC, Figure 3C ,F. Expression trends were not different in hyperdiploid ( Supplementary Figure 9 ) and non-hyperdiploid ( Supplementary Figure 10) subgroups, but a comparison between specific MYC abnormality groups shows that MYC and PVT1 expression is higher in hyperdiploidy group (Supplementary Figure 11) .
Integration of MYC Binding Sites with Over-expressed Genes Identifies Proliferation
Markers as Key Targets.
We went on to determine if there is a gene expression signature associated with MYC abnormalities. We compared samples with and without any structural change at 8q24 and Reactome 38 pathway analysis (for details of each gene see Supplementary Table 7 ).
We performed ChIP-seq against c-Myc and determined binding sites in two MM cell lines, MM.1S and KMS11, both of which have a MYC rearrangement. The peaks with a significance P < 10 -100 using MACS2 in either cell line were considered significant and accounted for 4.7% of peaks (1266/27006), Figure 8B . The peaks were compared to the 121 genes that were significantly changed in expression, Figure 8A . Six genes were in the intersection between over-expressed and significant peaks: HK2, MTHFD1L, SLC19A1, MFNG, SNHG4, GAS5, Figure 8C . Using less stringent ≥1.3 fold-change cut-off that provided 1801 genes of which 40.8% (735/1801) were overexpressed, the intersection of over-expressed genes and those with a significant MYC binding peak was 25.3% (186/735). At the top of the list of 186 genes ordered by ChIP-seq -log10 P, we detected upregulation of the genes with known or potential oncogenic activity such as genes promoting cell proliferation, tumor growth and/or inhibition of apoptosis (SNHG15, PPAN, MAT2A,   METAP1D , MTHFD2, SNHG17), translation factors (EIF3B, EIF4A1, EEF1B2) and genes involved in ribosome biosynthesis (RPL10A, RPL35, RPL23A, RPSA, RPL13, WDR43) .
Importantly, we identified HK2 and PVT1 as direct targets of MYC. HK2 is one of the most significant genes detected by ChIP-seq in both cell lines (-log10 P > 200, Figure 8C ) as well as having the highest fold-change using RNA-sequencing analysis ( Supplementary Table 7 ). This gene is an interesting direct target of MYC as it is part of the glucose metabolism pathway and would lead to increased energy metabolism and proliferation. PVT1 showed a smaller fold- 
Discussion
We show that MYC breakpoints in myeloma are clustered in three main hotspots on chromosome The scale of this analysis has allowed us to define the molecular breakpoints surrounding MYC with unparalleled accuracy and without technical bias. One of the two rearrangement hotspots involved in inter-chromosomal translocations in MM is also seen in other B cell malignancies. In Burkitt's lymphoma, two breakpoint clusters within exon 1 and intron 1 of MYC were defined, which corresponds in location to the non-Ig rearrangement hotspot in MM. 26 The same cluster is seen in diffuse large B cell lymphoma, where other random breakpoints are also seen scattered both centromeric and telomeric of MYC. 25 Both of these studies looked at relatively small numbers of samples (78 and 17, respectively) and used older techniques, such as long distance PCR and FISH, to detect the breakpoints. It may be that in other B cell malignancies there are also other breakpoint hotspots similar to MM.
The main chromosomal partner to MYC through inter-chromosomal rearrangements is chromosome 14, specifically the IGH locus. In Burkitt's lymphoma the IGH-MYC breakpoints on this chromosome lie almost exclusively within the switch regions (87%), upstream of the IGH constant regions. 26 The remaining 13% are within the joining region of the locus. These breakpoints are consistent with the IGH-MYC rearrangement being a primary event in Burkitt's lymphoma, occurring in 70-80% of patients. 40 In contrast, in MM we clearly see that IGH-MYC breakpoints within the IGH locus are not in the switch or joining regions. Instead, they are spread out across the constant regions of the locus. This spread is distinct from the five common primary translocation breakpoints in MM [t(4;14), t(11;14), etc.] which are restricted to the switch and joining regions. Even those with MYC breakpoints within switch regions (6.9% of IGH-MYC rearrangements) also have primary rearrangements or are hyperdiploid. This indicates that the IGH-MYC rearrangements are secondary events in MM and probably occur through a different molecular mechanism to the primary translocation events. It is known that the primary translocations in MM, and the IGH-MYC primary events in Burkitt's lymphoma, are mediated by AID and class switch recombination. 2, 4, 41 Therefore, the IGH-MYC rearrangements may occur through an as yet unknown, AID-independent, mechanism.
The mechanism driving MYC rearrangements is likely not to involve NHEJ, which would result in blunt ended rearrangements. 33 We have shown that MYC rearrangements are more likely to have short homologous sequences in common to both partner chromosomes, which is not seen as frequently in the primary IGH translocations. Short homologous sequences are indicative of MMEJ 42 , rather than NHEJ, and results through fork stalling and template switching during DNA replication or through microhomology-mediated break induced repair. 43, 44 The proteins involved in MMEJ include PARP1, Rad50, and Ercc1 whereas MMEJ is inhibited by functional ATM, H2AX, 53BP1 and BRCA1. 42 We have previously shown that mutation of ATM, BRCA1 and other genes involved in DNA homologous recombination are associated with in increased levels of loss of heterozygosity in MM patients. 45 It is likely that disruption of this pathway is key in genomic instability and progression of disease.
The non-Ig chromosomal partners of MYC are not random and are known to contain superenhancer elements. 5, 6 From our analysis of the breakpoints at the most frequent non-Ig locations (6p24.3 (TXNDC5/BMP6), 1p12 (FAM46C), 6q21 (FOXO3)) we show that the breakpoints at these genes are also clustered. The breakpoints are, in general, contained within TADs which are more likely to interact with one another. 46, 47 Each TAD at the partner chromosome contains a super-enhancer and breakpoints rarely fall outside of the TAD. The rearrangements are predicted to result in a changed TAD structure that places MYC in the same domain as the superenhancer from the partner locus. If breakpoints were to occur outside of the TAD with the superenhancer there would be a lower likelihood of it interacting with MYC and expression would not be enhanced.
We identified 149 partner loci for MYC rearrangements, but 67.2% of the samples with translocations involve one of the six main partners. The Ig partners have strong super-enhancers in MM, but there are many other active super-enhancers and so it is likely that these six main partners are constrained by chromatin structure. The breakpoints at 8q24 surround an epigenetically active region, defined by the active chromatin marks H3K27Ac, H3K36me3 and, H3K4me1 as well as DNaseI hypersensitivity sites. It may be that epigenetically active, and therefore accessible, loci are preferred translocation partners 48, 49 , and the nuclear localization of chromosomes may play a part too. 50 Each of these different rearrangements results in over-expression of MYC. MYC is not the only gene at 8q24, and indeed PVT1 is significantly over-expressed in our dataset. PVT1 is a long non-coding RNA and is associated with inhibition of apoptosis and increased proliferation. 51 It has also been shown that PVT1 interacts with MYC, resulting in a stable protein, and that ablation of PVT1 results in diminished tumorigenicity. 52 It may be that the gene complex encompassing MYC and PVT1 is required for oncogenesis and merits further study.
Other than PVT1, we also identified other genes that are direct targets of c-Myc and are overexpressed in 8q24-rearranged samples. These included HK2, a key enzyme involved in glucose metabolism. It has previously been shown that silencing of HK2 sensitizes cancer cells to other drugs, and so over-expression of HK2 in MYC-rearranged myeloma may be a key drug resistance mechanism. 53 Additional genes involved in important cellular functions that increase the oncogenic potential of myeloma cells were also identified, such as ribosome biosynthesis and translation initiation are likely to contribute to the poor prognosis seen in MYC-rearranged myeloma. 5, 14 Targeting MYC could therefore be and effective way to disrupt many essential tumor features in one hit.
This study provides evidence of complex chromosomal rearrangements at 8q24 as a key cause of MYC oncogenic up-regulation. Although we found that several MYC abnormalities are associated with prognosis in this dataset, including MYC-IGL and complex translocations, we have previously shown that the association is not independent of other genomic and clinical markers. 54 However, it may be possible that with longer follow-up MYC abnormalities may be independently associated with overall survival and be a marker of poor outcome. We also show a specific pattern of chromosomal breakpoints suggesting the role of the chromatin landscape in tumorigenesis. The mechanism of DNA breaks is clearly different between MYC rearrangements, resulting from MMEJ rather than NHEJ, and differs in myeloma compared to primary MYC translocations in lymphoma. 
